scholarly journals Long‐term cannabidiol treatment in patients with Dravet syndrome: An open‐label extension trial

Epilepsia ◽  
2018 ◽  
Vol 60 (2) ◽  
pp. 294-302 ◽  
Author(s):  
Orrin Devinsky ◽  
Rima Nabbout ◽  
Ian Miller ◽  
Linda Laux ◽  
Marta Zolnowska ◽  
...  
Keyword(s):  
Dravet Syndrome ◽  
Open Label ◽  
Open Label Extension ◽  
Extension Trial

Add‐on cannabidiol in patients with Dravet syndrome: Results of a long‐term open‐label extension trial

Epilepsia ◽  
2021 ◽  
Author(s):  
Ingrid E. Scheffer ◽  
Jonathan J. Halford ◽  
Ian Miller ◽  
Rima Nabbout ◽  
Rocio Sanchez‐Carpintero ◽  
...  
Keyword(s):  
Dravet Syndrome ◽  
Open Label ◽  
Open Label Extension ◽  
Extension Trial

scholarly journals Long‐term safety and efficacy of add‐on cannabidiol in patients with Lennox–Gastaut syndrome: Results of a long‐term open‐label extension trial

Epilepsia ◽  
2021 ◽  
Author(s):  
Anup D. Patel ◽  
Maria Mazurkiewicz‐Bełdzińska ◽  
Richard F. Chin ◽  
Antonio Gil‐Nagel ◽  
Boudewijn Gunning ◽  
...  
Keyword(s):  
Open Label ◽  
Safety And Efficacy ◽  
Open Label Extension ◽  
Extension Trial

Long-term safety and tolerability of iloperidone: results from a 25-week, open-label extension trial

CNS Spectrums ◽  
2013 ◽  
Vol 18 (1) ◽  
pp. 43-54 ◽  
Author(s):  
Andrew J. Cutler ◽  
Amir H. Kalali ◽  
Greg W. Mattingly ◽  
Jelena Kunovac ◽  
Xiangyi Meng
Keyword(s):  
Serum Glucose ◽  
Favorable Effect ◽  
Controlled Clinical Trial ◽  
Open Label ◽  
Once Daily ◽  
Syndrome Scale ◽  
Open Label Extension ◽  
Negative Syndrome ◽  
Extension Trial

Introduction/ObjectiveLong-term use of the atypical antipsychotic iloperidone has not been investigated at doses above 16 mg/d. This article describes safety and tolerability results from the 25-week open-label extension of a 4-week placebo- and ziprasidone-controlled clinical trial of iloperidone.MethodsPatients received a dose of 24 mg/d (given as 12 mg twice daily; mean dose = 21.6 mg) that could be reduced to 12 mg/d (given once daily at bedtime) any time after day 35 at the investigator's discretion.ResultsA total of 72/173 patients (41.6%) completed the open-label extension. Treatment-emergent adverse events (TEAEs), most mild to moderate in severity, included headache (13.9%), weight increase (9.2%), dizziness (6.9%), nausea (6.4%), sedation (6.4%), and insomnia (5.2%). The only notable dose-related TEAEs were increased weight and headache. Levels of serum glucose, lipids, and prolactin were essentially unchanged or decreased during treatment. In general, akathisia and extrapyramidal symptoms (EPS) improved or were unchanged during treatment. There was no signal of worsening of efficacy based on changes from baseline in the Positive and Negative Syndrome Scale-Total.Discussion/ConclusionThis study further supports the long-term safety and tolerability of iloperidone for the treatment of schizophrenia, including iloperidone's favorable effect on metabolic laboratory parameters and low propensity to cause akathisia or EPS.

Long-Term Safety, Tolerability, and Clinical Efficacy of Quetiapine in Adolescents: An Open-Label Extension Trial

2003 ◽  
Vol 13 (1) ◽  
pp. 75-82 ◽  
Author(s):  
Brian McConville ◽  
Lynn Carrero ◽  
Dennis Sweitzer ◽  
Larry Potter ◽  
Robert Chaney ◽  
...  
Keyword(s):  
Clinical Efficacy ◽  
Open Label ◽  
Open Label Extension ◽  
Extension Trial
Sign in / Sign up

Export Citation Format

Share Document